Digital thermal hyperaemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis

Rheumatology

Volumn 45, Issue 12, 2006, Pages 1490-1496

  Salvat Melis, M ^a   Carpentier, P H ^a   Minson, C T ^b   Boignard, A ^a   McCord, G R ^b   Paris, A ^a   Moreau Gaudry, A ^a   Cracowski, Jean Luc ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF OREGON   (United States)

Author keywords

Microcirculation; Raynaud's phenomenon; Systemic sclerosis; Vasodilatation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; AZATHIOPRINE; BOSENTAN; BUFLOMEDIL; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FINGER; FOREARM; HUMAN; HYPEREMIA; LASER DOPPLER FLOWMETRY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TEMPERATURE; VASCULAR DISEASE;

ADULT; BLOOD PRESSURE; FEMALE; FIBROSIS; FINGERS; FOREARM; HEAT; HUMANS; HYPEREMIA; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; VASODILATION;

EID: 33751404617     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel116     Document Type: Article

References (18)

1. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-33.
2. Charkoudian N. Skin blood flow in adult human thermoregulation: How it works, when it does not, and why. Mayo Clin Proc 2003;78:603-12.
3. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol 2001;91:1619-26.
4. Kellogg DL Jr, Liu Y, Kosiba IF, O'Donnell D. Role of nitric oxide in the vascular effects of local warming of the skin in humans. J Appl Physiol 1999;86:1185-90.
5. Boignard A, Salvat-Melis M, Carpentier P et al. Local hyperhemia to heating is impaired in secondary Raynaud's phenomenon. Arthritis Res Ther 2005;7:R1103-12.
6. Cazalets C, Cador B, Rolland Y et al. Digital flow exploration by color Doppler ultrasound in patients with Raynaud's disease or systemic sclerosis. J Mal Vasc 2004;29:12-20.
7. LeRoy EC, Medsger TA,Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
8. Leroy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
9. Leroy EC, Medsger TA,Jr. Raynaud's phenomenon: A proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
10. Furst DE, Clements PJ, Steen VD et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
11. Taylor MH, McFadden JA, Bolster MB, Silver RM. Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 2002;29:102-6.
12. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336:1530-3.
13. Rajagopalan S, Pfenninger D, Kehrer C et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis Rheum 2003;48:1992-2000.
14. Cracowski JL, Carpentier PH, Imbert B et al. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: Effect of cold exposure. Arthritis Rheum 2002;46:1319-23.
15. Wigley FM, Wise RA, Mikdashi J, Schaefer S, Spence RJ. The post-occlusive hyperemic response in patients with systemic sclerosis. Arthritis Rheum 1990;33:1620-5.
16. Minson CT, Wong BJ. Reactive hyperemia as a test of endothelial or microvascular function? J Am Coll Cardiol 2004;43:2147; author reply 2147-8.
17. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
18. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.